2026-07-21T07:57:50Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/166672024-11-28T19:25:03Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16964

00925njm 22002777a 4500 dc Caballero-Bermejo, Antonio F author Darnaude-Ximénez, Ignacio author Aguilar-Pérez, Myriam author Gomez-Lopez, Alicia author Sancho-López, Aránzazu author López García-Gallo, Cristina author Díaz Nuevo, Gema author Diago-Sempere, Elena author Ruiz-Antorán, Belén author Avendaño-Solá, Cristina author Ussetti-Gil, Piedad author PBISA01-Study Group author 2023-10-18 Isavuconazole's (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0061323. 10.1128/aac.00613-23 1098-6596 Antimicrobial agents and chemotherapy 37787528 http://hdl.handle.net/20.500.12105/16667 Isavuconazole Invasive fungal infection Bronchoalveolar lavage Tissue penetration Lung transplant Bronchopulmonary penetration of isavuconazole in lung transplant recipients